PG-102

DRUG3 trials

Sponsors

ProGen. Co., Ltd., RANI Therapeutics

Conditions

ObesityObesity Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

Phase 1

An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.

RecruitingNCT06891287

RANI TherapeuticsObesity

Start: 2025-12-30End: 2027-06-01Target: 60Updated: 2026-04-14

Phase 2

Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

Active, not recruitingNCT06712615

ProGen. Co., Ltd.Obesity Type 2 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)

Start: 2024-12-05End: 2025-10-30Target: 144Updated: 2025-07-11

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Not yet recruitingNCT07187856

ProGen. Co., Ltd.Type 2 Diabetes Mellitus (T2DM)

Start: 2026-01-31End: 2026-12-31Target: 80Updated: 2025-09-23